1.61
-0.02(-1.23%)
Currency In USD
| Previous Close | 1.63 |
| Open | 1.63 |
| Day High | 1.67 |
| Day Low | 1.61 |
| 52-Week High | 4.99 |
| 52-Week Low | 1.48 |
| Volume | 437,074 |
| Average Volume | 1.25M |
| Market Cap | 108.45M |
| PE | -2.04 |
| EPS | -0.79 |
| Moving Average 50 Days | 2.42 |
| Moving Average 200 Days | 2.64 |
| Change | -0.02 |
If you invested $1000 in Cardiff Oncology, Inc. (CRDF) 10 years ago, it would be worth $4.88 as of February 21, 2026 at a share price of $1.61. Whereas If you bought $1000 worth of Cardiff Oncology, Inc. (CRDF) shares 5 years ago, it would be worth $142.48 as of February 21, 2026 at a share price of $1.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 19, 2026 12:00 PM GMT
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
GlobeNewswire Inc.
Jan 27, 2026 12:05 PM GMT
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selec
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
GlobeNewswire Inc.
Jan 27, 2026 12:00 PM GMT
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition desi